271 related articles for article (PubMed ID: 22290257)
1. Antiangiogenic therapy for glioblastoma.
Gerstner ER; Batchelor TT
Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor therapy for malignant glioma.
Gerstner ER; Sorensen AG; Jain RK; Batchelor TT
Curr Neurol Neurosci Rep; 2009 May; 9(3):254-62. PubMed ID: 19348715
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
4. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
6. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
9. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
Takano S
Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
[TBL] [Abstract][Full Text] [Related]
11. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Wang N; Jain RK; Batchelor TT
Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
[TBL] [Abstract][Full Text] [Related]
12. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of VEGF in the treatment of glioblastoma.
Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
[TBL] [Abstract][Full Text] [Related]
14. VEGF inhibitors in brain tumors.
Brastianos PK; Batchelor TT
Clin Adv Hematol Oncol; 2009 Nov; 7(11):753-60, 768. PubMed ID: 20075834
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab antiangiogenic therapy for glioblastoma.
Junck L
Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
[No Abstract] [Full Text] [Related]
16. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
de Groot J; Reardon DA; Batchelor TT
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714460
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
de Boüard S; Guillamo JS
Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
[TBL] [Abstract][Full Text] [Related]
18. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
Henriksson R; Bergström P; Johansson M; Sandström M
Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
[No Abstract] [Full Text] [Related]
19. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.
Grodzik M; Sawosz E; Wierzbicki M; Orlowski P; Hotowy A; Niemiec T; Szmidt M; Mitura K; Chwalibog A
Int J Nanomedicine; 2011; 6():3041-8. PubMed ID: 22162660
[TBL] [Abstract][Full Text] [Related]
20. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
Gerstner ER; Emblem KE; Sorensen GA
Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
